Fostamatinib Medication Guide

Fostamatinib (Fostamatinib) is a drug used to treat adult patients with chronic immune thrombocytopenia (ITP) who have had an inadequate response to previous treatments. The following is the detailed administration method of fotantinib:

When initiating treatment, the recommended initial dose of fotantinib is100 mg orally twice daily. If the patient's platelet count fails to increase to at least 50×10^9/L after one month, the dose can be increased to 150 mg daily and continued to be taken twice daily. The basic goal of fotantinib is to achieve and maintain a platelet count of at least 50×10^9/L with the lowest effective dose to reduce the risk of bleeding. Patients can choose to take fotantinib before or after meals. If a dose is missed, please instruct the patient to take it promptly at the next prescribed time.

After the baseline assessment, a complete blood count (CBC) including platelet count should be monitored monthly until the platelet count stabilizes at at least 50×10^9/L. Complete blood counts, including neutrophils, should still be checked regularly after stabilization. At the same time, liver function tests (LFTs), such as ALT, AST, and bilirubin, are performed monthly. Blood pressure monitoring should be performed every two weeks until stable dosage is confirmed, then monthly monitoring may be performed.

The dose of fotantinib may need to be adjusted based on patient safety and tolerability. If patients experience adverse reactions when receiving the maximum dose, dose reduction may be considered. For example, if a patient experiences adverse reactions at the maximum daily dose of 300 mg, the dose can be adjusted to 200 mg/day for the first time, or further reduced to 150 mg/day, or 100 mg/day (it is recommended to take it once in the morning). If further reduction of dose to less than 100 mg/day is required, fotantinib should be discontinued.

Fortantinib should be discontinued if, after 12 weeks of treatment, the patient's platelet count has not increased to a safe level sufficient to avoid clinically important bleeding.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21149cc3-049b-43e2-b141-c9499160556c